Review



hbg bc2  (Inserm Transfert)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Inserm Transfert hbg bc2
    Hbg Bc2, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hbg-bc2(+)/bc2+hbg/pmc12624014-52-11-14
    Average 86 stars, based on 1 article reviews
    hbg bc2 - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas
    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Isolation:

    Article Title: Autumn meeting 2000
    Article Snippet: 4 Differential effects of selective retinoic acid receptor RAR-y agonists CD437 and CD666 on apoptosis and cell cycle arrest in normal and transformed human airway epithelial



    Similar Products

    hbg bc2  (Inserm Transfert)
    86
    Inserm Transfert hbg bc2
    Hbg Bc2, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hbg-bc2(+)/bc2+hbg/pmc12624014-52-11-14
    Average 86 stars, based on 1 article reviews
    hbg bc2 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    hbg-bc2( )  (Inserm Transfert)
    90
    Inserm Transfert hbg-bc2( )
    (A) Aldolase B (left y-axis) and CD44 (right y-axis) mRNA expression throughout the culture of HepaRG, <t>BC2,</t> Huh7, HepG2 and Huh6 cell lines: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated and Pro=proliferative. Results are expressed relative to progenitors for HepaRG or proliferative cells for BC2, Huh7, HepG2 and Huh6 (n≥3). Comparison with spheres *p<0.05, **p<0.01, ***p<0.001; comparison with SP $ p<0.05, $$ p<0.01, $$$ p<0.001 (B) Glycolysis, glycolytic capacity, basal and maximal respiration assessed with Seahorse analyzer for HepaRG, BC2, Huh7, HepG2 and Huh6 (n≥3). (C) Lactate and β-hydroxybutyrate assessed in culture supernatants by absorption spectrophotometry (n≥3). FAO and de novo lipogenesis assessed by quantifying the radioactivity subsequent to 14 C-palmitate and 14 C-acetate incorporation, respectively (n≥3). FAT/CD36 mRNA expression relative to progenitors for HepaRG and proliferative cells for BC2, Huh7, HepG2 and Huh6 (n>=3). Neutral lipid content assessed by nile red staining (n≥3). (D) Quantification by gas chromatography-mass spectrometry of fatty acids (FA) from cell total lipids (total FAs), triglycerides, phospholipids, cholesterol esters and free FAs in HepaRG and BC2 at different stages of differentiation. The saturated/unsaturated FA ratio is calculated from data obtained with the total lipid pool. Results are normalized by the number of cells (n≥3). *p<0.05, **p<0.01, ***p<0.001.
    Hbg Bc2( ), supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hbg-bc2(+)/hbg+bc2+++/bio_rxiv__2024__09__02__610533-50-11-13
    Average 90 stars, based on 1 article reviews
    hbg-bc2( ) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    human hepatoma hbg bc2 cells  (Inserm Transfert)
    90
    Inserm Transfert human hepatoma hbg bc2 cells
    (A) Aldolase B (left y-axis) and CD44 (right y-axis) mRNA expression throughout the culture of HepaRG, <t>BC2,</t> Huh7, HepG2 and Huh6 cell lines: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated and Pro=proliferative. Results are expressed relative to progenitors for HepaRG or proliferative cells for BC2, Huh7, HepG2 and Huh6 (n≥3). Comparison with spheres *p<0.05, **p<0.01, ***p<0.001; comparison with SP $ p<0.05, $$ p<0.01, $$$ p<0.001 (B) Glycolysis, glycolytic capacity, basal and maximal respiration assessed with Seahorse analyzer for HepaRG, BC2, Huh7, HepG2 and Huh6 (n≥3). (C) Lactate and β-hydroxybutyrate assessed in culture supernatants by absorption spectrophotometry (n≥3). FAO and de novo lipogenesis assessed by quantifying the radioactivity subsequent to 14 C-palmitate and 14 C-acetate incorporation, respectively (n≥3). FAT/CD36 mRNA expression relative to progenitors for HepaRG and proliferative cells for BC2, Huh7, HepG2 and Huh6 (n>=3). Neutral lipid content assessed by nile red staining (n≥3). (D) Quantification by gas chromatography-mass spectrometry of fatty acids (FA) from cell total lipids (total FAs), triglycerides, phospholipids, cholesterol esters and free FAs in HepaRG and BC2 at different stages of differentiation. The saturated/unsaturated FA ratio is calculated from data obtained with the total lipid pool. Results are normalized by the number of cells (n≥3). *p<0.05, **p<0.01, ***p<0.001.
    Human Hepatoma Hbg Bc2 Cells, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hbg-bc2(+)/hbg+bc2+++/10__1191_slash_096032701671015886-71-0-7
    Average 90 stars, based on 1 article reviews
    human hepatoma hbg bc2 cells - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Aldolase B (left y-axis) and CD44 (right y-axis) mRNA expression throughout the culture of HepaRG, BC2, Huh7, HepG2 and Huh6 cell lines: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated and Pro=proliferative. Results are expressed relative to progenitors for HepaRG or proliferative cells for BC2, Huh7, HepG2 and Huh6 (n≥3). Comparison with spheres *p<0.05, **p<0.01, ***p<0.001; comparison with SP $ p<0.05, $$ p<0.01, $$$ p<0.001 (B) Glycolysis, glycolytic capacity, basal and maximal respiration assessed with Seahorse analyzer for HepaRG, BC2, Huh7, HepG2 and Huh6 (n≥3). (C) Lactate and β-hydroxybutyrate assessed in culture supernatants by absorption spectrophotometry (n≥3). FAO and de novo lipogenesis assessed by quantifying the radioactivity subsequent to 14 C-palmitate and 14 C-acetate incorporation, respectively (n≥3). FAT/CD36 mRNA expression relative to progenitors for HepaRG and proliferative cells for BC2, Huh7, HepG2 and Huh6 (n>=3). Neutral lipid content assessed by nile red staining (n≥3). (D) Quantification by gas chromatography-mass spectrometry of fatty acids (FA) from cell total lipids (total FAs), triglycerides, phospholipids, cholesterol esters and free FAs in HepaRG and BC2 at different stages of differentiation. The saturated/unsaturated FA ratio is calculated from data obtained with the total lipid pool. Results are normalized by the number of cells (n≥3). *p<0.05, **p<0.01, ***p<0.001.

    Journal: bioRxiv

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

    doi: 10.1101/2024.09.02.610533

    Figure Lengend Snippet: (A) Aldolase B (left y-axis) and CD44 (right y-axis) mRNA expression throughout the culture of HepaRG, BC2, Huh7, HepG2 and Huh6 cell lines: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated and Pro=proliferative. Results are expressed relative to progenitors for HepaRG or proliferative cells for BC2, Huh7, HepG2 and Huh6 (n≥3). Comparison with spheres *p<0.05, **p<0.01, ***p<0.001; comparison with SP $ p<0.05, $$ p<0.01, $$$ p<0.001 (B) Glycolysis, glycolytic capacity, basal and maximal respiration assessed with Seahorse analyzer for HepaRG, BC2, Huh7, HepG2 and Huh6 (n≥3). (C) Lactate and β-hydroxybutyrate assessed in culture supernatants by absorption spectrophotometry (n≥3). FAO and de novo lipogenesis assessed by quantifying the radioactivity subsequent to 14 C-palmitate and 14 C-acetate incorporation, respectively (n≥3). FAT/CD36 mRNA expression relative to progenitors for HepaRG and proliferative cells for BC2, Huh7, HepG2 and Huh6 (n>=3). Neutral lipid content assessed by nile red staining (n≥3). (D) Quantification by gas chromatography-mass spectrometry of fatty acids (FA) from cell total lipids (total FAs), triglycerides, phospholipids, cholesterol esters and free FAs in HepaRG and BC2 at different stages of differentiation. The saturated/unsaturated FA ratio is calculated from data obtained with the total lipid pool. Results are normalized by the number of cells (n≥3). *p<0.05, **p<0.01, ***p<0.001.

    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Techniques: Expressing, Comparison, Spectrophotometry, Radioactivity, Staining, Gas Chromatography, Mass Spectrometry

    (A) Upper left panel: PPAR mRNA expression throughout the differentiation process of HepaRG and BC2 cells: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated, Pro=proliferative, Hep=freshly isolated human hepatocytes. Results are expressed relative to HepaRG-progenitors or BC2-proliferative cells (n≥3). *, $ and # for PPARG , PPARD and PPARA , respectively; $ p<0.05; **, $$, ##p<0,01; ***, $$$, ###p<0,001; all compared with spheres. Upper right panel: Western Blot of PPARγ, PPARα and HSC70 in HepaRG and BC2 cells. Lower left panel: PPARG mRNA expression in HepaRG progenitors treated with SC-79 or LY294002 during 24, 48 or 72h. Lower right panel: Western Blot and densitometry of AKT and phosphoAKT (pAKT) in HepaRG progenitors treated with SC-79 or LY294002 during 24 or 72h. *p<0.05; **p<0,01; ***p<0,001. (B) Overall survival according to PPARG and/or PPARA expression in the TCGA-LIHC cohort. (C) Correlation between PPARG and PPARA expression and AFP level in the TCGA-LIHC cohort. (D) PPARG and PPARA expression in the Désert’s HCC subclasses. Results are expressed relative to PPARG and PPARA levels in the periportal subclass. ***p<0.001. (E) Immunostaining of PPARγ in human HCC. Both the tumor (left) and a tumor nodule invading adjacent tissue (right) show nuclear and cytoplasmic signal. Black arrows indicate a nuclear localization of PPARγ.

    Journal: bioRxiv

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

    doi: 10.1101/2024.09.02.610533

    Figure Lengend Snippet: (A) Upper left panel: PPAR mRNA expression throughout the differentiation process of HepaRG and BC2 cells: Sph=spheres, SP=side population, Prog=progenitors, Conf=committed/confluent, Diff=differentiated, Pro=proliferative, Hep=freshly isolated human hepatocytes. Results are expressed relative to HepaRG-progenitors or BC2-proliferative cells (n≥3). *, $ and # for PPARG , PPARD and PPARA , respectively; $ p<0.05; **, $$, ##p<0,01; ***, $$$, ###p<0,001; all compared with spheres. Upper right panel: Western Blot of PPARγ, PPARα and HSC70 in HepaRG and BC2 cells. Lower left panel: PPARG mRNA expression in HepaRG progenitors treated with SC-79 or LY294002 during 24, 48 or 72h. Lower right panel: Western Blot and densitometry of AKT and phosphoAKT (pAKT) in HepaRG progenitors treated with SC-79 or LY294002 during 24 or 72h. *p<0.05; **p<0,01; ***p<0,001. (B) Overall survival according to PPARG and/or PPARA expression in the TCGA-LIHC cohort. (C) Correlation between PPARG and PPARA expression and AFP level in the TCGA-LIHC cohort. (D) PPARG and PPARA expression in the Désert’s HCC subclasses. Results are expressed relative to PPARG and PPARA levels in the periportal subclass. ***p<0.001. (E) Immunostaining of PPARγ in human HCC. Both the tumor (left) and a tumor nodule invading adjacent tissue (right) show nuclear and cytoplasmic signal. Black arrows indicate a nuclear localization of PPARγ.

    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Techniques: Expressing, Isolation, Western Blot, Immunostaining

    (A) PPARG mRNA expression 48h after transfection of HepaRG-spheres with siNon-targeting (siNT) and siPPARG (n=3). Sphere number and ATP viability assay 48h after seeding of transfected HepaRG cells in sphere culture medium (n=3). ATP viability assay of HepaRG- and -spheres after treatment with 50µM or 100µM rosiglitazone during 72h (n=4). (B) ATP viability assay of HepaRG-progenitors and BC2-proliferative cells after treatment with 50µM or 100µM rosiglitazone during 72h (n=3). HepaRG and BC2 proliferation assessed by quantifying empty areas using ImageJ, three days after seeding. (n=3). (C) mRNA expression of E-cadherin ( CDH1 ), fatty acid transporter FAT/CD36 , PDK4 , perilipin2 ( PLIN2 ), EMT-inducing transcription factor SNAIL and stem-related marker KLF4 in HepaRG-progenitors and BC2- proliferative cells after treatment with rosiglitazone (50 or 100µM) during 72h (n=3). (D) Confocal microscopy of mitochondrial protein TOM22 immunostaining in HepaRG-progenitors 48h after treatment with 50µM rosiglitazone or transfection with siPPARG. Bar=10µm. Mitochondrial network branching and length analyzed using ImageJ (n=3). Mitochondrial DNA assessed by RT-qPCR, 24h, 48h and 72h after transfection of HepaRG-progenitors with siPPARG (n=4). (E) Basal respiration, maximal respiration, spare respiratory capacity and respiration linked to ATP production assessed with Seahorse analyzer in HepaRG-progenitors treated by rosiglitazone 50µM during 48h (n=3). Results are expressed relative to untreated cells or siNT. *p<0.05, **p<0.01, ***p<0.001

    Journal: bioRxiv

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

    doi: 10.1101/2024.09.02.610533

    Figure Lengend Snippet: (A) PPARG mRNA expression 48h after transfection of HepaRG-spheres with siNon-targeting (siNT) and siPPARG (n=3). Sphere number and ATP viability assay 48h after seeding of transfected HepaRG cells in sphere culture medium (n=3). ATP viability assay of HepaRG- and -spheres after treatment with 50µM or 100µM rosiglitazone during 72h (n=4). (B) ATP viability assay of HepaRG-progenitors and BC2-proliferative cells after treatment with 50µM or 100µM rosiglitazone during 72h (n=3). HepaRG and BC2 proliferation assessed by quantifying empty areas using ImageJ, three days after seeding. (n=3). (C) mRNA expression of E-cadherin ( CDH1 ), fatty acid transporter FAT/CD36 , PDK4 , perilipin2 ( PLIN2 ), EMT-inducing transcription factor SNAIL and stem-related marker KLF4 in HepaRG-progenitors and BC2- proliferative cells after treatment with rosiglitazone (50 or 100µM) during 72h (n=3). (D) Confocal microscopy of mitochondrial protein TOM22 immunostaining in HepaRG-progenitors 48h after treatment with 50µM rosiglitazone or transfection with siPPARG. Bar=10µm. Mitochondrial network branching and length analyzed using ImageJ (n=3). Mitochondrial DNA assessed by RT-qPCR, 24h, 48h and 72h after transfection of HepaRG-progenitors with siPPARG (n=4). (E) Basal respiration, maximal respiration, spare respiratory capacity and respiration linked to ATP production assessed with Seahorse analyzer in HepaRG-progenitors treated by rosiglitazone 50µM during 48h (n=3). Results are expressed relative to untreated cells or siNT. *p<0.05, **p<0.01, ***p<0.001

    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Techniques: Expressing, Transfection, Viability Assay, Marker, Confocal Microscopy, Immunostaining, Quantitative RT-PCR

    (A) Phase-contrast microscopy of HepaRG-progenitors and BC2-proliferative cells 48h after transfection with siPPARG. Bar=100µm. (B) mRNA expression of PPARG , PLIN2 and PDK4 , 48h and 72h after transfection of siPPARG in HepaRG-progenitors and BC2-proliferative cells (n=3). (C) Basal respiration, maximal respiration, spare respiratory capacity, proton leak, respiration linked to ATP production and non-mitochondrial oxygen consumption, assessed with Seahorse analyzer in HepaRG-progenitors, 48h after transfection of siPPARG (n=3). Results are expressed relative to siNT. (D) Basal respiration, maximal respiration and proton leak assessed with Seahorse analyzer in HepaRG-spheres treated by DCA (50mM) during 4h. Results are expressed relative to untreated HepaRG-spheres (n>=3). *p<0.05, **p<0.01, ***p<0.001.

    Journal: bioRxiv

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

    doi: 10.1101/2024.09.02.610533

    Figure Lengend Snippet: (A) Phase-contrast microscopy of HepaRG-progenitors and BC2-proliferative cells 48h after transfection with siPPARG. Bar=100µm. (B) mRNA expression of PPARG , PLIN2 and PDK4 , 48h and 72h after transfection of siPPARG in HepaRG-progenitors and BC2-proliferative cells (n=3). (C) Basal respiration, maximal respiration, spare respiratory capacity, proton leak, respiration linked to ATP production and non-mitochondrial oxygen consumption, assessed with Seahorse analyzer in HepaRG-progenitors, 48h after transfection of siPPARG (n=3). Results are expressed relative to siNT. (D) Basal respiration, maximal respiration and proton leak assessed with Seahorse analyzer in HepaRG-spheres treated by DCA (50mM) during 4h. Results are expressed relative to untreated HepaRG-spheres (n>=3). *p<0.05, **p<0.01, ***p<0.001.

    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Techniques: Microscopy, Transfection, Expressing

    (A) PPARG and PPARA expression in HepaRG progenitors after treatment during 72h with cisplatin (10µl/ml) or sorafenib (2.5µM) (n=4). **p<0,01 (B) Superoxide anion production (ROS) assessed by Mitosox® in HepaRG-spheres after 50 µM dicloroacetate (DCA) treatment during 12h, 24h, 48h and 72h (n=4) or in HepaRG progenitors after 12h, 24h, 48h and 72h transfection with siPPARG or siNT (n=4). *p<0.05; **p<0,01 (C) Viability of HepaRG- progenitors and BC2-proliferative cells transfected with siPPARG or siNT and treated with cisplatin (10µg/ml for HepaRG; 20µg/ml for BC2) or sorafenib (2.5µM for HepaRG; 15µM for BC2) or 50mM DCA during 48h. Results are expressed relative to untransfected/untreated cells (n=4 for HepaRG and n=3 for BC2). *, #, $ in comparison to siNT, untreated siNT and untreated siPPARG, respectively. (D) Viability of HepaRG-progenitors pre-incubated 24h or not with N-acetyl-cysteine (NAC, 1mM) and treated during 48h with cisplatin (10µg/ml) or sorafenib (2.5µM) combined or not with T0070907 (10µM). Results are expressed relative to untreated cells (n=3). *, T0070907 vs untreated; #, cisplatin or sorafenib vs untreated; $, cisplatin or sorafenib vs cisplatin or sorafenib combined with T0070907. (E) Viability, superoxide anion production, lipid peroxidation assessed by malondialdehyde formation in HepaRG transfected with siPPARG or siNT, pre-incubated 48h or not with NAC (1mM) and treated during 48h with cisplatin (10µg/ml) or sorafenib (2.5µM). *, NAC vs without NAC; #, cisplatin or sorafenib vs untreated; $, siPPARG vs siNT. (F) Viability of HepaRG- and BC2-spheres pre-treated 24h with clofibrate (100 or 500µM) and then treated with sorafenib (2.5µM for HepaRG; 15µM for BC2) and/or DCA (50mM) during 72h. Results are expressed relative to untreated cells (n=4 for HepaRG and n=3 for BC2). *, #, $ p<0.05; **, $$ p<0.01; ***, ###, $$$ p<0.001. ****, #### p<0.0001.

    Journal: bioRxiv

    Article Title: PPARγ, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

    doi: 10.1101/2024.09.02.610533

    Figure Lengend Snippet: (A) PPARG and PPARA expression in HepaRG progenitors after treatment during 72h with cisplatin (10µl/ml) or sorafenib (2.5µM) (n=4). **p<0,01 (B) Superoxide anion production (ROS) assessed by Mitosox® in HepaRG-spheres after 50 µM dicloroacetate (DCA) treatment during 12h, 24h, 48h and 72h (n=4) or in HepaRG progenitors after 12h, 24h, 48h and 72h transfection with siPPARG or siNT (n=4). *p<0.05; **p<0,01 (C) Viability of HepaRG- progenitors and BC2-proliferative cells transfected with siPPARG or siNT and treated with cisplatin (10µg/ml for HepaRG; 20µg/ml for BC2) or sorafenib (2.5µM for HepaRG; 15µM for BC2) or 50mM DCA during 48h. Results are expressed relative to untransfected/untreated cells (n=4 for HepaRG and n=3 for BC2). *, #, $ in comparison to siNT, untreated siNT and untreated siPPARG, respectively. (D) Viability of HepaRG-progenitors pre-incubated 24h or not with N-acetyl-cysteine (NAC, 1mM) and treated during 48h with cisplatin (10µg/ml) or sorafenib (2.5µM) combined or not with T0070907 (10µM). Results are expressed relative to untreated cells (n=3). *, T0070907 vs untreated; #, cisplatin or sorafenib vs untreated; $, cisplatin or sorafenib vs cisplatin or sorafenib combined with T0070907. (E) Viability, superoxide anion production, lipid peroxidation assessed by malondialdehyde formation in HepaRG transfected with siPPARG or siNT, pre-incubated 48h or not with NAC (1mM) and treated during 48h with cisplatin (10µg/ml) or sorafenib (2.5µM). *, NAC vs without NAC; #, cisplatin or sorafenib vs untreated; $, siPPARG vs siNT. (F) Viability of HepaRG- and BC2-spheres pre-treated 24h with clofibrate (100 or 500µM) and then treated with sorafenib (2.5µM for HepaRG; 15µM for BC2) and/or DCA (50mM) during 72h. Results are expressed relative to untreated cells (n=4 for HepaRG and n=3 for BC2). *, #, $ p<0.05; **, $$ p<0.01; ***, ###, $$$ p<0.001. ****, #### p<0.0001.

    Article Snippet: We used 2 human HCC cell lines established in our laboratory, HBG-BC2( ) (Inserm UMR 1317, ex Inserm U 49) and HepaRG( ) (Inserm UMR 1317, ex Inserm UMR 552, Patent number US7456018).

    Techniques: Expressing, Transfection, Comparison, Incubation